How long does it take for ozanimod to take effect?

Ozamod (ozanimod) is an oral prescription drug approved for the treatment of multiple sclerosis and moderately to severely active ulcerative colitis. Ozamod may work quickly in multiple sclerosis (MS) within months, although it may take up to a year to see significantly less disease progression, fewer relapses and less brain shrinkage than with standard treatment.

The study showed a trend toward reduced disease progression in patients taking ozanimod compared with interferon-beta-1a within 3 months of dosing (7.6% of ozanimod patients had disease progression) , After one year of treatment, 78% of patients taking Ozamod remained relapse-free, and 76% of patients taking Ozamod remained relapse-free after 2 years. Patients who received ozanimod for one year had significantly fewer new or enlarging T2 hyperintense lesions on MRI compared with the interferon group (48% relative reduction). The number of GdE lesions was also significantly reduced in the ozanimod group compared with interferon (63% relative reduction). These significant results persisted over the two-year study, although the relative reductions were slightly smaller (46% for T2 lesions and 53% for GdE lesions).

In patients with moderately to severely active ulcerative colitis (UC), reduced rectal bleeding and stool frequency were observed as early as week 2, and significant differences in clinical remission, clinical response, and endoscopic improvement were seen within 10 weeks of starting ozanimod compared with placebo. In True North, a Phase 3 trial comparing ozanimod to placebo in adults with moderately to severely active UC, 18% of those taking ozanimod achieved the primary endpoint of clinical remission at week 10, compared with 6% of those taking placebo. Secondary endpoints were also met, including clinical response (48% vs. 26%), endoscopic improvement (27% vs. 12%), and endoscopic histological mucosal improvement (13% vs. 4%) for ozanimod vs. placebo, respectively. In the maintenance portion of the trial, the primary endpoint of clinical response (37% vs. 19%) and key secondary endpoints including clinical response (60% vs. 41%), endoscopic improvement (46% vs. 26%), corticosteroid-free clinical response (32% vs. 17%), and endoscopic histological mucosal improvement (30% vs. 14%) were each maintained at Week 52.

The original drug Ozamod has been launched in China, but it has been on the market for a short time and has not been included in the medical insurance. The specific price is not yet clear, and domestic purchase channels are relatively difficult. Specifications of OzamodOriginal Drug Launched OverseasThe price of 0.92*28 capsules per box may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod available on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.